SCHEMBL6479909

SCHEMBL6479909

COC(=O)c1ccc2cc(C(C)=O)oc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 1/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CREBBP Q92793 1/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GLA P06280 2/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 2/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
HSD17B10 Q99714 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
BRCA1 P38398 1/20 0.47
MAPT P10636 2/20 0.45
ATM Q13315 1/20 0.45
CA9 Q16790 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28125379 0.90 PSMB8 (0.54) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL6480210 0.88 PSMB8 (0.51) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL6479111 0.88 PSMB8 (0.51) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL3721459 0.88 LMNA (0.59) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL24176986 0.85 ALDH1A1 (0.54) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL28375846 0.83 PSMB8 (0.52) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL15349478 0.82 PSMB8 (0.47) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL6478966 0.82 SMN1; SMN2 (0.51) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL28125380 0.81 KDM4E (0.46) PSMB8NPC1RAB9AMEN1KMT2A
SCHEMBL6090295 0.81 PSMB8 (0.54) PSMB8NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894042-B2 Azabicyclic compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY (US) 2005-05-17 US disclosed
EP-1476448-A2 AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-11-17 EP disclosed
US-20040224976-A1 Azabicyclic compounds for the treatment of disease WALKER DANIEL PATRICK (US) 2004-11-11 US disclosed
US-20030232853-A1 Azabicyclic compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-18 US disclosed
WO-2003070731-A2 AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232853-A1 Azabicyclic compounds for the treatment of disease TPMT, MALT1, AZI2 PSMB8 3719/4885NPC1 284/4885RAB9A 1279/4885
US-20040224976-A1 Azabicyclic compounds for the treatment of disease TPMT, MALT1, AZI2 PSMB8 3719/4885NPC1 284/4885RAB9A 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.